HZNP Stock Recent News
HZNP LATEST HEADLINES
ABNB, SIGA, DRQ, SWRAY and HZNP have been added to the Zacks Rank #1 (Strong Buy) List on April 14, 2023.
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
Horizon Therapeutics (HZNP) possesses solid growth attributes, which could help it handily outperform the market.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Horizon Therapeutics (HZNP) reports better-than-expected fourth-quarter 2022 results as it beats the Zacks Consensus Estimate for both revenues and earnings.
While the top- and bottom-line numbers for Horizon Therapeutics (HZNP) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 11.01% and 1.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Two billionaires –Paul Tudor Jones and George Soros — acquired shares of Horizon Therapeutics (NASDAQ: HZNP ) stock, a drugmaker, last quarter. On Dec. 12, Horizon agreed to be acquired by a giant pharmaceutical company, Amgen (NASDAQ: AMGN ).
Horizon Therapeutics (HZNP) announces that a phase II Sjogren's syndrome study of its candidate, dazodalibep, meets the primary endpoint for the second population.
HZNP vs. RGEN: Which Stock Is the Better Value Option?